COMPARE · Data as of August 21, 2026
BSX vs DXCM
Verdict: Side-by-side breakdown using the Bull Rankings model. BSX scored 78.1, DXCM scored 77.5 — BSX leads.
Compare another set
BSX
Boston Scientific Corporation
78.1
$50.37 · $73.0B
fundamentals as of
Score gap
0.6
BSX leads
DXCM
DexCom, Inc.
77.5
$92.34 · $34.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBSX20.4x
- Fastest growthDXCM+15.5%
- Strongest balance sheetBSX0.50
- Highest qualityDXCM91 / 100
- Largest discount to fair valueBSX-12%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
BSX
stronger →← stronger
DXCM
71
Qualityreturns · margins · balance sheet
91
88
Growthrevenue & earnings expansion
89
76
Valuevaluation vs sector peers
58
DXCM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BSX
DXCM
$3.6bB
FCF
$1.4bC+
+13.5%B+
Rev
+15.5%B+
0.50B
D/E
0.53B
20.4xB+
P/E
36.5xC+
0.75A-
PEG
1.70C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BSX
DXCM
12% below
Price vs fair valuelower is cheaper
64% above
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~24%/yr
+12%
1-yr DCF upside
-49%
+14%
5-yr DCF upside
-39%
+16%
10-yr DCF upside
-22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BSX
Why this score
- Buying back stock
DXCM
Why this score
- Buying back stock
- Durable high returns
The companies
BSXBoston Scientific Corporation
Why now
Medical Devices · market cap $73.0b. Down 54% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +24% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 54% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
DXCMDexCom, Inc.
Why now
Medical Devices · market cap $34.8b. Trading near 52-week high of $92.56 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $94.12 (implying +2% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BSX and DXCM diverge
On the headline score the gap is 0.6 points in favor of BSX. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityBSX 71.2 · DXCM 90.6DXCM +19.4
- ValueBSX 75.8 · DXCM 57.6BSX +18.2
- GrowthBSX 88.4 · DXCM 89.5level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.